FDA Brief

Warning letters Drugs

FDA warning letter to

Bespoke Apothecary LLC

LowIssued Sep 28, 2022Posted Sep 29, 2022Center for Drug Evaluation and Research | CDER

Bespoke Apothecary sold COVID kit and herbal tea with unapproved COVID-19 treatment claims, FDA and FTC say.

What happened

FDA reviewed the company's website on September 7, 2022, and the FTC reviewed it on September 26, 2022, along with linked Facebook and Instagram pages. The review found the COVID kit and Post Virus Recovery Herbal Tea offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. FDA calls the products unapproved new drugs and misbranded drugs.

What FDA found

  1. The COVID kit and Post Virus Recovery Herbal Tea are unapproved new drugs because they are sold with claims to treat or prevent COVID-19 without FDA approval.

    FD&C Act section 505(a), 21 U.S.C. § 355(a)
  2. The products are misbranded because their labeling makes misleading COVID-19 treatment and prevention claims.

    FD&C Act section 502, 21 U.S.C. § 352
  3. Putting these products into interstate commerce is prohibited.

    FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)
  4. The company advertised that its products can prevent, treat, or cure disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. Deceptive COVID-19 treatment, cure, prevention, or mitigation claims can carry civil penalties under the COVID-19 Consumer Protection Act.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA tells the company to stop selling any unapproved or unauthorized COVID-19 products immediately and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and how it will prevent recurrence.

Who should pay attention

  • online herbal and supplement sellers
  • marketplaces and social media sellers making health claims
  • regulatory teams reviewing COVID-19 and disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk